Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

被引:0
|
作者
Lumei Kang
Yuyang Tian
Shilin Xu
Hongping Chen
机构
[1] Medical College,Department of Animal Science
[2] Nanchang University,Department of Histology and Embryology, Medical College
[3] Nanchang University,Jiangxi Key Laboratory of Experimental Animals
[4] Nanchang University,undefined
来源
Journal of Neurology | 2021年 / 268卷
关键词
Oxaliplatin; Neuropathy; Clinical features; Prevention and treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Oxaliplatin (OXA) is a commonly used platinum-based chemotherapy drug for colorectal cancer. OXA-induced peripheral neurotoxcity (OIPN) is a comprehensive adverse reaction of OXA. OIPN can be divided into acute and chronic types according to clinical features and different mechanisms. The main clinical features of acute OIPN are cold-sensitive sensory symptoms and neuropathic pain in limbs. In addition to the above symptoms, chronic OIPN also produces autonomic nerve dysfunction. The most important mechanism involved in acute OIPN is the alteration of voltage-gated Na + channels, and nuclear DNA damage in chronic OIPN. There are some methods like reducing exposure to cold, calcium and magnesium salts, amifostine could be beneficial in acute OIPN prevention and dose modification, changing in schedule glutathione, duloxetine, selective serotonin reuptake inhibitors, carbonic anhydrase inhibitor in chronic OIPN prevention. Recent updates are provided in this article in relation to the clinical features, potential mechanisms, prevention and treatment of OIPN.
引用
收藏
页码:3269 / 3282
页数:13
相关论文
共 50 条
  • [21] Endothelial Glycocalyx in the Peripheral Capillaries is Injured Under Oxaliplatin-Induced Neuropathy
    Kuroda, Takahiro
    Suzuki, Akio
    Okada, Hideshi
    Shimizu, Masayoshi
    Watanabe, Daichi
    Suzuki, Keiko
    Mori, Kosuke
    Ohmura, Kazufumi
    Niwa, Ayumi
    Imaizumi, Yuko
    Matsuo, Mikiko
    Ichihashi, Koki
    Okubo, Takafumi
    Taniguchi, Toshiaki
    Kanayma, Tomohiro
    Kobayashi, Ryo
    Sugie, Shigeyuki
    Hara, Akira
    Tomita, Hiroyuki
    JOURNAL OF PAIN, 2024, 25 (06)
  • [22] A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration
    A. J. M. Beijers
    F. Mols
    G. Vreugdenhil
    Supportive Care in Cancer, 2014, 22 : 1999 - 2007
  • [23] Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity
    Salat, Kinga
    PHARMACOLOGICAL REPORTS, 2020, 72 (03) : 508 - 527
  • [24] A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration
    Beijers, A. J. M.
    Mols, F.
    Vreugdenhil, G.
    SUPPORTIVE CARE IN CANCER, 2014, 22 (07) : 1999 - 2007
  • [25] Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral Neuropathy in Rats
    Choi, Seunghwan
    Chae, Hyeon Kyeong
    Heo, Ho
    Hahm, Dae-Hyun
    Kim, Woojin
    Kim, Sun Kwang
    TOXINS, 2019, 11 (07)
  • [26] Modulation of HCN channel activity in oxaliplatin-induced peripheral neuropathy
    Morez, M.
    Aissouni, Y.
    Prival, L.
    Barbier, J.
    Balayssac, D.
    Taillefumier, C.
    Roy, O.
    Bourinet, E.
    Wersinger, E.
    Busserolles, J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 10 - 11
  • [27] Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review
    Pulvers, Jeremy N.
    Marx, Gavin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (06) : 345 - 355
  • [28] Role of Pregabalin in Treatment of Oxaliplatin-induced Sensory Neuropathy
    Saif, Muhammad Wasif
    Syrigos, Kostas
    Kaley, Kristin
    Isufi, Iris
    ANTICANCER RESEARCH, 2010, 30 (07) : 2927 - 2933
  • [29] Impact of oxaliplatin-induced neuropathy: a patient perspective
    Bennett, Barbara K.
    Park, Susanna B.
    Lin, Cindy S. -Y.
    Friedlander, Michael L.
    Kiernan, Matthew C.
    Goldstein, David
    SUPPORTIVE CARE IN CANCER, 2012, 20 (11) : 2959 - 2967